Multiple Endocrine Neoplasia Type 2
Last Posted: Jun 06, 2019
- Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
Raue Friedhelm et al. The Journal of clinical endocrinology and metabolism 2019 May
- Patient quality of life and prognosis in multiple endocrine neoplasia type 2.
Grey Joanna et al. Endocrine-related cancer 2018 25(2) T69-T77
- CLINGEN Actionability Report for Multiple Endocrine Neoplasia IIA, Familial Medullary Thyroid Cancer - RET
ClinGen Actionability Working Group
- Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.
Parkhurst Emily et al. Journal of genetic counseling 2018 Jun
- Secondary findings from next-generation sequencing: what does actionable in childhood really mean?
Richer Julie et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Jun
- [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Shimodaira Hideki et al. Gan to kagaku ryoho. Cancer & chemotherapy 2018 Apr 45(4) 587-592
- The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
Zupan Andrej et al. Exp. Mol. Pathol. 2015 Aug 27.
- RET gene abnormalities and thyroid disease: who should be screened and when.
- Thyroid CancerPatient Version
- Multiple endocrine neoplasia type 1
From NCATS Genetic and Rare Diseases Information Center
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.